**BOOK BEFORE 18TH JANUARY, 2019 AND SAVE UP TO €800**

**April 23-25, 2019** | Amsterdam, Netherlands

**www.neoantigen-europe.com**

# European NeoAg Summit

## Supercharging Cell Immunotherapies & Cancer Vaccines



- **Optimising neoantigen prediction and immune response**
- **Streamlining personalised manufacturing to scale out effectively**
- **Navigate the evolving regulatory landscape for clarity on approval**

## Expert Speakers Include:

**Laurence Cooper**
CEO
**Ziopharm**

**Jessica Flechtner**
CSO
**Genocea**

**Agnete Fredricksen**
Chief Scientific Officer
**Vaccibody**

**John Castle**
Head of Translational Medicine & Bioinformatics
**Agenus**

**Mathias Vormehr**
Head of Cancer Vaccines
**BioNTech**

**Jennifer Busby**
Senior Director of Mass Spectrometry & Proteomics
**Gritstone Oncology**

**Asterios Tsiftsoglou**
CAT Committee Member
**EMA**

**Lélia Delamarre**
Senior Scientist, Cancer Immunology Research
**Genentech**

**Andrew Ishizuka**
CSO
**Avidea Technologies**

**Partners:** OncoImmunity Personalis ALMAC

**Tel:** +44 (0)20 3141 8700 **Email:** info@hansonwade.com Neoantigens in Immunotherapy

hansonwade

# Welcome to the 3rd European NeoAg Summit

With a record number of drug developers moving into and through the clinic with neoantigen targeted cancer immunotherapies, the **European NeoAg Summit** provides you with an industry focused guide to maximising clinical success and faster approval.

Join the gathering of over 100 personalised cancer immunotherapy pioneers from pharma and biotech to advance neoantigen based cancer vaccines and cell therapies.

With an exclusive case-study led agenda, this year's summit will paint a fuller picture of **neoantigen presentation** and **T-cell interaction**. Hear updates on **clinical trials results** to help you further determine **neoantigen immunogenicity**.

In addition, gain practical insights on **personalised cancer vaccine and cell therapy manufacturing**, and **regulatory guidance** from the **European Medicines Agency**.

Leave equipped with the knowledge and connections to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.

## What previous attendees have said about our meetings

"This meeting was a very efficient way to meet the companies and hear the main players in the field discuss the technologies and the clinical endeavors to use neoantigens in various types of immunotherapy"
**Medigene**

"The best conference I have found that focuses specifically on neoantigens"
**ACT Genomics**

## Top 5 Reasons to Attend:

**1.** **Determine the immune response of neoantigens** with case studies from **Genentech** and **BioNtech**

**2.** **Improve clinical relevance of your predicted neoantigens.** Gain insights from bioinformatics and bioassay techniques with **Agenus** and **Genocea**

**3.** **Optimise your clinical development** by learning from the challenges and successes of running clinical trials with **Vaccibody**

**4.** **Understand the European regulatory landscape** by gaining guidance from Committee of Advanced Therapies at the **European Medicines Agency**

**5.** **Overcome clinical and logistical challenges** of personalised cell therapy with the latest developments from **Immatics** and **Ziopharm**

# YOUR EXPERT SPEAKERS

**John Castle**
Associate Vice President, Head of Translational Medicine & Bioinformatics
**Agenus**

**Hans Keirstead**
Chief Executive Officer
**AIVITA Biomedical**

**Andrew Ishizuka**
Chief Scientific Officer
**Avidea Technologies**

**Mathias Vormehr**
Head of Cancer Vaccines
**BioNTech**

**Michal Bassani-Sternberg**
Director, Immunopeptidomics Unit, Center of Experimental Therapeutics
**CHUV**

**Asterios Tsiftsoglou**
Committee for Advanced Therapies Member
**European Medicines Agency**

**Lélia Delamarre**
Senior Scientist, Cancer Immunology Research
**Genentech**

**Jessica Flechtner**
Chief Scientific Officer
**Genocea**

**Jennifer Busby**
Senior Director of Mass Spectrometry & Proteomics
**Gritstone Oncology**

**Norbert Hilf**
Director of Translational Development
**Immatics**

**John Wang**
Chief Executive Officer
**IOVaxis**

**Ying He**
Associate Director
**Jiangsu Hengrui Medicine**

**Trevor Clancy**
Chief Scientific Officer
**OncoImmunity**

**Sean Boyle**
Director, Bioinformatics Applications
**Personalis**

**Agnete Fredriksen**
Chief Scientific Officer
**Vaccibody**

**Laurence Cooper**
Chief Executive Officer
**ZIOPHARM Oncology**

> "This meeting was the most comprehensive survey of the emerging field of neoantigen-based therapeutics with excellent speakers"
>
> **Argos Therapeutics**

# FOCUS DAY
# TUESDAY, 23RD APRIL

## Spotlight Workshop A — 9.00am-12.00pm

### Neoantigen Identification to Ensure Immunogenic & Clinically Relevant Neoantigens

HLA binding affinity, T cell bioassays and Immunopeptidomics have all been recognised to have key advantages and disadvantages in the neoantigen selection process.

Through the presentation of the latest case studies and structured discussions, attendees will leave with novel insights on neoantigen calling processes.

**Join this workshop to learn and discuss:**

- Key advances in *in silico* MHC ligand prediction through mass spectrometry data
- Minimising time and cost of the neoantigen selection, prediction and validation process
- Challenges and improvements in predicting the T-cell reponse

**Michal Bassani-Sternberg**
Director, Immunopeptidomics Unit, Center of Experimental Therapeutics
**CHUV**

Michal Bassani-Sternberg is heading the Immunopeptidomics unit that is integrated within the Center of Experimental Therapeutic (CTE) in the department of Oncology at the CHUV, Lausanne, Switzerland, where she integrates mass spectrometry based immunopeptidomics into the innovative translational clinical strategy of personalised immunotherapy. In the last ten years, Dr Bassani-Sternberg has focused her research mainly on the development of methodologies for highly accurate and in-depth immunopeptidomics. She has completed her PhD at the Faculty of Biology at the Technion - Israel Institute of Technology and post-doctorate at the Proteomics and Signal Transduction Department, headed by Prof. Matthias Mann at the Max Planck Institute of Biochemistry. Recently she has integrated next generation sequencing with immunopeptidomics to directly identify patient's specific neo-epitopes presented on melanoma tissues.

## Spotlight Workshop B — 1.00pm-4.00pm

### Regulatory Pathway & Landscape for Neoantigen-based Cancer Immunotherapy

As the cell therapy and cancer vaccine space advances and clinical investigations continue to produce promising results, uncertainty about the regulatory frameworks and procedures in place needs to be addressed.

**In this workshop, attendees will learn and discuss:**

- Current regulatory requirements in the clinical development and manufacturing of neoantigen based cancer immunotherapy
- Requirements to demonstrate convincing efficacy in neoantigen targeting
- What are the key considerations to take into account when working with regulatory body?

**Asterios Tsiftsoglou**
Committee for Advanced Therapies Member
**European Medicines Agency**

Dr Asterios Tsiftsoglou is currently a member of Committee for Advanced Therapies at the European Medicines Agency. He is also Professor of Pharmacology at the Department of Pharmaceutical Sciences at Aristotle University of Thessaloniki. Prior to his current position, he was Assistant Professor of Medicine (Hematology-Oncology) at Harvard Medical School. Dr Tsiftsoglou obtained his M.Sci. and PhD in Pharmacology from Yale University. and carried out Postdoctoral Research in the Center for Cancer Research.at MIT, Cambridge, MA.USA

# CONFERENCE DAY ONE
# WEDNESDAY, 24TH APRIL

**8.30** **Registration & Coffee**

**9.15** **Chair's Opening Remarks**

## Approaches to Improve Neoantigen Predication

**9.30** **Neoantigen Prediction: Approach & Validation**

**Jennifer Busby**
Senior Director of Mass Spectrometry & Proteomics
**Gritstone Oncology**

- Most solid tumour patients could benefit from personalised immunotherapy against private neoantigens – discussing the critical need for neoantigen identification and product manufacturing
- Addressing the significant challenge of neoantigen identification for cancer immunotherapy
- Understanding how tumour immunopeptidomics combined with deep learning provides a powerful approach for neoantigen prediction
- Evaluating Gritstone's EDGETM prediction model which identifies therapeutically relevant neoantigens

**10.00** **A Non-Functional Neoepitope Specific CD8+ T-cell Response Induced by Tumour Derived Antigen Exposure *In Vivo***

**Mathias Vormehr**
Head of Cancer Vaccines **BioNTech**

- High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the Tumour specific T-cell response are of interest
- We analysed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumour inflammation and cell death in mice
- Review how all tested treatment regimens were found to induce a single significant CD8+ T-cell response which was not able to recognise and kill tumor cells
- Evaluate the presented data which exemplifies that neo-antigen specific T cells primed by tumour-released antigen exposure might not always be functionally relevant as previously expected

**10.30** **An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens**

**Trevor Clancy**
Chief Scientific Officer
**OncoImmunity**

- Outlining a high-performing machine learning approach, trained on massspectrometry data, that predicts naturally processed and presented antigens
- Demonstrating how the predictor is integrated with several immune parameters, such as HLA binding, in a deep learning layer to predict bone fide neoantigens
- Illustrating its application to significantly improve the identification of neoantigen targets for personalised cancer immunotherapy

**11.00** **Speed Networking & Morning Refreshments**

## Enhancing the Validation of Neoantigens to Ensure Immunogenicity

**12.00** **Connecting Neoantigens to TCR Recognition**

**John Castle**
Associate Vice President, Head of Translational Medicine & Bioinformatics
**Agenus**

Evaluating how:

- Not all aberrations are equal in the eyes of the immune system
- Only some non-self aberrations are processed and presented
- Only some presented peptides are recognised and impart effective immune response
- TCRs have a defined specificity for recognition

**12.30** **Obtaining a Fuller Picture of Immunogenicity to Improve Neoantigen Selection**

- Reviewing important parameters to consider for neo-epitope selection
- Improving neoantigen prediction for MHC II peptides
- Comparing and contrasting methods for prediction for better T cell epitope discovery
- Balancing high throughput capabilities while selecting all presented and immunogenic MHC ligands

**John Castle**
Associate Vice President, Head of Translational Medicine & Bioinformatics
**Agenus**

**Lélia Delamarre**
Senior Scientist, Cancer Immunology Research
**Genentech**

**Jennifer Busby**
Senior Director of Mass Spectrometry & Proteomics
**Gritstone Oncology**

**1.30** **Lunch & Networking**

**Sean Boyle**
Director, Bioinformatics Applications
**Personalis**

**2.30** **ImmunoID NeXT Platform: Improving Neoantigen Prediction, TME Assessment & ctDNA Detection for Vaccine Development**

- Exploring innovative genomics methods for a more comprehensive assessment of neoantigens
- Improving neoantigen to MHC binding prediction and ranking
- Assessing TME/TCR and tumour escape mechanisms that may impact vaccine response

**Lélia Delamarre**
Senior Scientist, Cancer Immunology Research
**Genentech**

**3.00** **Determinants of Cancer Neoantigen Immunogenicity**

**3.30** **Afternoon Break & Poster Session**

**4.00** **Roundtable Discussion:**

Be part of practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. This is a valuable chance for you to unite with your peers around hot topics and debate best practice.

**1**

**Identifying Shared/ Public Neoantigens to Benefit a Greater Number of Patients**

**2**

**Assessing Optimal Combination Therapies Involving Neoantigen Based Vaccines and Cell Therapies**

**3**

**Understanding the Influence of Tumour Microenvironment and Mechanisms of Immunosuppression**

**5.00** **Chair's Closing Remarks**

**5.15** **End of Day One**

"Great opportunity to learn how to develop and accelerate neoantigen-related products not only from speakers but also participants and partners"

**BrightPath Biotherapeutics**

# CONFERENCE DAY TWO
# THURSDAY, 25TH APRIL

**8.30** **Coffee & Networking**

**9.15** **Chair's Opening Remarks**

## Driving the Prioritsation & Characterisation of Neoantigens

**Laurence Cooper**
Chief Executive Officer
**Ziopharm**

**9.30** **One for All & All for One – Bioengineering of T cells with Specificity for Neoantigens in Solid Tumours**

- Targeting of solid tumours based on the identification and prioritisation of neoantigens
- Targeting of neoantigens based on the identification and prioritisation of T-cell receptors (TCRs)
- Using *Sleeping Beauty* system to express neoantigen-specific TCRs in clinical grade T cells

**Norbert Hilf**
Director of Translational Development
**Immatics**

**10.00** **Integrating Non-Mutated & Neoantigens into Highly Personalised Immunotherapy Approaches – Clinical Experiences**

- Reviewing the role of neoantigens and non-mutated antigens in tumours with low mutational burden
- Understand the GAPVAC approach: concept of actively personalised vaccination in newly diagnosed glioblastoma
- Analysing final results of the GAPVAC-101 study with a focus on biological activity data
- Assessing challenges for personalised immunotherapies
- Going beyond GAPVAC: highly personalised Adoptive Cellular Therapy

**Jessica Flechtner**
Chief Scientific Officer
**Genocea**

**10.30** **Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification & Characterisation**

- Assessing how HLA agnostic assay identifies CD4 and CD8 T cell neoantigens
- Analysing the uniquely distinguished mutations that elicit stimulatory and inhibitory T cell responses
- Novel updates on clinical development of personalised neoantigen vaccine based on ATLAS platform

**11.00** **Morning Refreshments & Networking**

## Evaluating the Clinical Development of Personalised Cancer Immunotherapy

**Agnete Fredriksen**
Chief Scientific Officer
**Vaccibody**

**12.00** **Bringing Individualised Neoantigen-based Cancer Vaccines into the Clinic; Challenges, Learnings & Victories**

- Overcoming the hurdles of moving into a new field that challenges standard regulatory guidelines
- How to meet the demands on lead time, COGS and efficacy for individual vaccines
- How to deal with the rapid evolvement of combination strategies
- An update on Vaccibody's VB N-01 study using personalised vaccines in patients with advanced cancer

**Hans Keirstead**
Chief Executive Officer
**AIVITA Biomedical**

**12.30 Next Generation Immunotherapy Targeting the Cancer Stem Cell**

- AIVITA Biomedical has developed a personalized cancer immunotherapy consisting of autologous dendritic cells loaded with autologous tumor antigens from autologous self-renewing tumor-initiating cells.
- Successive manufacturing improvements have rendered the treatment economical and reliable to produce. The treatment is in Phase 2 clinical trials for glioblastoma and ovarian cancer, and AIVITA is also seeking conditional approval to commercialize for melanoma in Japan.
- Mechanism of action analyses have determined tumorigenicity and driver immunogenicity of the isolated tumor-initiating cells, changes in the blood of responsive patients that are consistent with the induction of a Th17 cytotoxic response, as well as surrogate and predictive markers of efficacy.
- Exomic analyses with HLA profiling on multiple patient samples have identified common driver neo-antigens

**1.00 Lunch & Networking**

**2.00 Panel Discussion: Global Clinical Development of Neoantigen-based Cancer Therapies**

**Jessica Flechtner**
Chief Scientific Officer
**Genocea**

**Agnete Fredriksen**
Chief Scientific Officer
**Vaccibody**

**John Wang**
Chief Executive Officer
**IOVaxis**

**Andrew Ishizuka**
Chief Scientific Officer
**Avidea Technologies**

**3.00 Induction of Neoantigen-specific T cells with Self-Assembling Nanoparticles**

- Exploring the properties of peptide-based vaccines that impact CD8 T cell induction
- Evaluating self-assembling nanoparticles as a modular platform for optimising T cell responses
- Analysing the effect of vaccine dose, route, and TLR-7/8 agonist potency on T cell induction in mice and primates

**3.30 Chair's Closing Remarks**

**3.45 Close of 3rd Annual European NeoAg Summit**

"The Neoantigen Summit was a great meeting which enabled me to learn a lot whilst making some great connections! This is a fast-moving field and meetings like this are incredibly important to keep the people involved moving forward. Very well organised conference. Very pleased!"

**Meditope Biosciences**

# PARTNERS

## Industry Development Partner

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.

**www.oncoimmunity.com**

## Expertise Partner

Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.

**www.personalis.com**

## Exhibitor

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

**www.almacgroup.com/api-chemicaldevelopment**

## TYPES OF COMPANIES ATTENDING*




*Based on market research and previous events' statistics

## TYPES OF COMPANIES ATTENDING*




*Based on market research and previous events' statistics

## GET INVOLVED

**Jennifer Mackay**
Senior Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

# READY TO REGISTER?

## 3 EASY WAYS TO BOOK

neoantigen-europe.com/register

Tel: +44 (0)20 3141 8700

Email: register@hansonwade.com

## Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

REGISTER BY JANUARY 18TH 2019 **AND SAVE UP TO €800**

# SECURE YOUR PLACE

| **Pharma & Biotech Drug Developers*** | Register & Pay by Friday 18th January, 2019** | Standard Rate |
|---|---|---|
| Conference + 2 Workshops | €2797 + VAT **(save €800)** | €3397 + VAT **(save €200)** |
| Conference + 1 Workshop | €2298 + VAT **(save €700)** | €2898 + VAT **(save €100)** |
| Conference Only | €1799 + VAT **(save €600)** | €2399 + VAT |
| Workshop Only (each) | €599 + VAT | |

| **Solution/Service Provider Pricing** | Register & Pay by Friday 18th January, 2019 | Standard Rate |
|---|---|---|
| Conference + 2 Workshops | €3997 + VAT **(save €800)** | €4597 + VAT **(save €200)** |
| Conference + 1 Workshop | €3398 + VAT **(save €700)** | €3998 + VAT **(save €100)** |
| Conference Only | €2799 + VAT **(save €600)** | €3399 + VAT |
| Workshop Only (each) | €699 + VAT | |

*Academic discount available. Please email info@hansonwade.com for more information.
**VAT will be charged at 21%



# VENUE

**Amsterdam Marriot Hotel**
Stadhouderskade 12, 1054 ES
Amsterdam, Netherlands

**For further information or assistance, please visit www.marriott.co.uk/hotels/travel/amsnt-amsterdam-marriott-hotel**



Code: 11425